In summary using samples from our multicenter feasibility study we present novel evidence that targeted albumin infusions seem to exert a beneficial immune effect in patients with AD/ACLF via its ability to bind PGE2, but do not reduce overall total circulating levels. This evidence concerns the gene ALB and Alzheimer disease.